$ATAI
ATAI Life Sciences NV Stock $atai

$atai Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-K Financial Statement

#000095017022005013 Filed on March 30, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021
Revenue	$0.00	$230.0K	$20.38M
YoY Change	-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$17.98M	$25.88M	$92.75M
YoY Change	93.92%	-64.05%	14.88%
% of Gross Profit
Research & Development	$15.46M	$12.98M	$47.96M
YoY Change	176.81%	287.52%	320.37%
% of Gross Profit
Depreciation & Amortization	$60.00K	$29.00K	$47.00K
YoY Change	900.0%	107.14%	95.83%
% of Gross Profit
Operating Expenses	$33.44M	$38.86M	$156.2M
YoY Change	111.26%	-48.42%	49.94%
Operating Profit	-$33.44M		-$135.8M
YoY Change	-925.73%		30.38%
Interest Expense	$2.261M	-$3.656M	-$3.419M
YoY Change	1170.22%	-1067.2%	-117.03%
% of Operating Profit
Other Income/Expense, Net	$1.521M	$252.0K	-$796.0K
YoY Change	-10.69%	-106.5%	-133.89%
Pretax Income	-$31.92M	-$48.58M	-$136.6M
YoY Change	-654.86%	-46.76%	34.17%
Income Tax	$41.00K	-$4.421M	-$3.989M
% Of Pretax Income
Net Earnings	-$36.87M	-$88.88M	-$167.8M
YoY Change	-5458.87%	2.64%	-1.2%
Net Earnings / Revenue		-38642.17%	-823.56%
Basic Earnings Per Share	-$0.24		-$1.21
Diluted Earnings Per Share	-$0.24	-$592.3K	-$1.214M
COMMON SHARES
Basic Shares Outstanding	160.7M	160.3M	138.3M
Diluted Shares Outstanding	153.5M		138.3M

Balance Sheet

Concept	2022 Q1	2021 Q4	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$334.9M	$362.3M	$362.3M
YoY Change			272.7%
Cash & Equivalents	$124.0M	$362.3M	$362.3M
Short-Term Investments	$210.9M
Other Short-Term Assets	$1.389M	$756.0K	$6.497M
YoY Change		36.46%	490.64%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$348.8M	$375.1M	$375.1M
YoY Change		276.79%	276.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$178.0K	$149.0K	$149.0K
YoY Change		109.86%	49.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$9.749M	$16.13M	$27.76M
YoY Change			246.99%
Other Assets	$7.504M	$7.341M	$7.341M
YoY Change		2065.49%	286.37%
Total Long-Term Assets	$34.95M	$39.08M	$39.08M
YoY Change		225.7%	225.7%
TOTAL ASSETS
Total Short-Term Assets	$348.8M	$375.1M	$375.1M
Total Long-Term Assets	$34.95M	$39.08M	$39.08M
Total Assets	$383.7M	$414.2M	$414.2M
YoY Change		271.29%	271.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.612M	$6.004M	$6.004M
YoY Change		94.75%	93.68%
Accrued Expenses	$18.25M	$14.83M	$6.692M
YoY Change		60.92%	-27.26%
Deferred Revenue
YoY Change
Short-Term Debt	$210.9M	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$22.09M	$20.94M	$20.94M
YoY Change		70.23%	70.2%
LONG-TERM LIABILITIES
Long-Term Debt	$725.0K	$743.0K	$743.0K
YoY Change			-62.85%
Other Long-Term Liabilities	$4.126M	$4.097M	$6.529M
YoY Change			243.63%
Total Long-Term Liabilities	$4.126M	$4.097M	$7.272M
YoY Change			86.46%
TOTAL LIABILITIES
Total Short-Term Liabilities	$22.09M	$20.94M	$20.94M
Total Long-Term Liabilities	$4.126M	$4.097M	$7.272M
Total Liabilities	$29.38M	$28.21M	$37.26M
YoY Change		74.33%	79.99%
SHAREHOLDERS EQUITY
Retained Earnings	-$394.7M	-$357.8M
YoY Change		88.32%
Common Stock	$18.01M	$18.00M
YoY Change		34.62%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$346.0M	$376.9M	$376.9M
YoY Change
Total Liabilities & Shareholders Equity	$383.7M	$414.2M	$414.2M
YoY Change		271.29%	271.45%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021
OPERATING ACTIVITIES
Net Income	-$36.87M	-$88.88M	-$167.8M
YoY Change	-5458.87%	2.64%	-1.2%
Depreciation, Depletion And Amortization	$60.00K	$29.00K	$47.00K
YoY Change	900.0%	107.14%	95.83%
Cash From Operating Activities	-$23.99M	-$20.51M	-$63.25M
YoY Change	45.16%	230.05%	204.57%
INVESTING ACTIVITIES
Capital Expenditures	$56.00K	-$357.0K	$173.0K
YoY Change	-68.0%	614.0%	193.22%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$48.28M	$0.00
YoY Change	-100.0%	1165.09%	-100.0%
Cash From Investing Activities	-$214.7M	-$48.63M	-$81.28M
YoY Change	5670.92%	1157.97%	187.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$1.000M		-$409.4M
YoY Change	-96.48%		-596.59%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	132.0K	1.723M	409.9M
YoY Change	-99.57%	-97.9%	262.54%
NET CHANGE
Cash From Operating Activities	-23.99M	-20.51M	-63.25M
Cash From Investing Activities	-214.7M	-48.63M	-81.28M
Cash From Financing Activities	132.0K	1.723M	409.9M
Net Change In Cash	-238.3M	-67.42M	265.0M
YoY Change	-3445.37%	-193.77%	294.47%
FREE CASH FLOW
Cash From Operating Activities	-$23.99M	-$20.51M	-$63.25M
Capital Expenditures	$56.00K	-$357.0K	$173.0K
Free Cash Flow	-$24.04M	-$20.15M	-$63.42M
YoY Change	43.97%	226.93%	204.53%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
CY2021Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1654
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020	us-gaap	Proceeds From Sale Of Land Held For Use ProceedsFromSaleOfLandHeldForUse
CY2021	atai	Loss On Asset Acquisition Of A Variable Interest Entity LossOnAssetAcquisitionOfAVariableInterestEntity
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001840904
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1
CY2021	atai	Effect Of German Participation Exemption On Outside Basis Differences EffectOfGermanParticipationExemptionOnOutsideBasisDifferences
CY2021	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2020	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal
CY2020	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1
CY2021	us-gaap	Origination Of Notes Receivable From Related Parties OriginationOfNotesReceivableFromRelatedParties
CY2021	us-gaap	Increase Decrease In Notes Receivable Related Parties Current IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent
CY2021	atai	Deferred Offering Costs In Accounts Payable DeferredOfferingCostsInAccountsPayable
CY2020	atai	Gain Loss On Conversion Of Notes Related Party GainLossOnConversionOfNotesRelatedParty
CY2020	atai	Effect Of Share Based Compensation Expense EffectOfShareBasedCompensationExpense
CY2020	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss
CY2020	us-gaap	Other Payments To Acquire Businesses OtherPaymentsToAcquireBusinesses
CY2020	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets
CY2021	atai	Effect Of Non Deductible Compensation In Respect Of Convertible Notes EffectOfNonDeductibleCompensationInRespectOfConvertibleNotes
CY2020	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware
CY2020	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal
CY2020	atai	Fair Value Of Redeemable Non Controlling Interests Issued In Connection With Consolidation Of Variable Interest Entity FairValueOfRedeemableNonControllingInterestsIssuedInConnectionWithConsolidationOfVariableInterestEntity
CY2021Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1350
CY2020	atai	Loss On Conversion Of Convertible Notes LossOnConversionOfConvertibleNotes
CY2021	atai	Common Stock Issuance Costs In Accrued Liabilities CommonStockIssuanceCostsInAccruedLiabilities
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt
CY2021	atai	Effect Of Conversion Of Convertible Notes EffectOfConversionOfConvertibleNotes
CY2021	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue
CY2021	atai	Change In Fair Value Of Convertible Promissory Note ChangeInFairValueOfConvertiblePromissoryNote
CY2021	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering
CY2020	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties
CY2021Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1350
CY2020	atai	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2021Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1654
CY2020	atai	Proceeds From Sale Of Investment ProceedsFromSaleOfInvestment
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
CY2020	atai	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability
CY2021	us-gaap	Increase Decrease In Notes Receivable Related Parties Current IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	00000
CY2020	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss
CY2020	atai	Fair Value Of Non Controlling Interests Issued In Connection With Consolidation Of Variable Interest Entity FairValueOfNonControllingInterestsIssuedInConnectionWithConsolidationOfVariableInterestEntity
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-40493
CY2021	dei	Entity Registrant Name EntityRegistrantName	ATAI Life Sciences N.V.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	P7
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	ATAI Life Sciences N.V. c/o Mindspace
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Krausenstraße 9-10
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Berlin
CY2021	dei	Entity Address Country EntityAddressCountry	DE
CY2021	dei	City Area Code CityAreaCode	49 89
CY2021	dei	Local Phone Number LocalPhoneNumber	2153 9035
CY2021	dei	Security12b Title Security12bTitle	Common shares, par value €0.10 per share
CY2021	dei	Trading Symbol TradingSymbol	ATAI
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	2050000000.00
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	160709397
CY2021	dei	Auditor Firm AuditorFirmId	34
CY2021	dei	Auditor Name AuditorName	DELOITTE & TOUCHE LLP
CY2021	dei	Auditor Location AuditorLocation	Parsippany, New Jersey
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	362266000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	97246000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11903000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2076000
CY2021Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	913000
CY2020Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	0
CY2021Q4	us-gaap	Notes Receivable Related Parties Current NotesReceivableRelatedPartiesCurrent	0
CY2020Q4	us-gaap	Notes Receivable Related Parties Current NotesReceivableRelatedPartiesCurrent	226000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	375082000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	99548000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	149000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	71000
CY2021Q4	atai	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	0
CY2020Q4	atai	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	1575000
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	16131000
CY2020Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0
CY2021Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	11628000
CY2020Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	8044000
CY2021Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	0
CY2020Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	911000
CY2021Q4	us-gaap	Notes Receivable Related Parties Noncurrent NotesReceivableRelatedPartiesNoncurrent	3835000
CY2020Q4	us-gaap	Notes Receivable Related Parties Noncurrent NotesReceivableRelatedPartiesNoncurrent	1060000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7341000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	339000
CY2021Q4	us-gaap	Assets Assets	414166000
CY2020Q4	us-gaap	Assets Assets	111548000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6004000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3083000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14829000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9215000
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	51000
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	51000
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	0
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20935000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12298000
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2432000
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1705000
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	743000
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	1199000
CY2021Q4	atai	Convertible Promissory Notes And Derivative Liability Noncurrent Related Party ConvertiblePromissoryNotesAndDerivativeLiabilityNoncurrentRelatedParty	0
CY2020Q4	atai	Convertible Promissory Notes And Derivative Liability Noncurrent Related Party ConvertiblePromissoryNotesAndDerivativeLiabilityNoncurrentRelatedParty	300000
CY2021Q4	atai	Convertible Promissory Notes And Derivative Liability Noncurrent ConvertiblePromissoryNotesAndDerivativeLiabilityNoncurrent	0
CY2020Q4	atai	Convertible Promissory Notes And Derivative Liability Noncurrent ConvertiblePromissoryNotesAndDerivativeLiabilityNoncurrent	978000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4097000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0
CY2021Q4	us-gaap	Liabilities Liabilities	28207000
CY2020Q4	us-gaap	Liabilities Liabilities	16180000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.12
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.12
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	173116704
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	160677001
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	160677001
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	114735712
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	114735712
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	18002000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	13372000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	725045000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	261626000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8336000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5819000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-357803000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-189995000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	376908000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	90822000
CY2021Q4	us-gaap	Minority Interest MinorityInterest	9051000
CY2020Q4	us-gaap	Minority Interest MinorityInterest	4546000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	385959000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	95368000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	414166000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	111548000
CY2021	us-gaap	Revenues Revenues	20376000
CY2020	us-gaap	Revenues Revenues	0
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	47956000
CY2020	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	11408000
CY2021	atai	Acquisition Of In Process Research And Development AcquisitionOfInProcessResearchAndDevelopment	15480000
CY2020	atai	Acquisition Of In Process Research And Development AcquisitionOfInProcessResearchAndDevelopment	12020000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	92745000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	80734000
CY2021	us-gaap	Operating Expenses OperatingExpenses	156181000
CY2020	us-gaap	Operating Expenses OperatingExpenses	104162000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-135805000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-104162000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	205000
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	71000
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-173000
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1133000
CY2020	us-gaap	Increase Decrease In Notes Receivable Related Parties Current IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent	718000
CY2021	atai	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	0
CY2020	atai	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	-16974000
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-41000
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-150000
CY2021	atai	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-87000
CY2021	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-12346000
CY2020	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount	19856000
CY2021	atai	Gain Loss On Conversion Of Notes Related Party GainLossOnConversionOfNotesRelatedParty	-513000
CY2021	us-gaap	Variable Interest Entity Activity Between Vie And Entity Operating Income Or Loss VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss	0
CY2020	us-gaap	Variable Interest Entity Activity Between Vie And Entity Operating Income Or Loss VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss	-504000
CY2021	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	3543000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	8481000
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-194000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-293000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	359000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-796000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2349000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-136601000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-101813000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3989000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	305000
CY2021	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	16923000
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-58555000
CY2020	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-76507000
CY2021	us-gaap	Profit Loss ProfitLoss	-174244000
CY2020	us-gaap	Profit Loss ProfitLoss	-178625000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-6436000
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-8782000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-167808000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-169843000
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.21
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.83
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	138265859
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	93019072
CY2021	us-gaap	Profit Loss ProfitLoss	-174244000
CY2020	us-gaap	Profit Loss ProfitLoss	-178625000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-14155000
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	7245000
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-188399000
CY2020	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-171380000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-6436000
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-8782000
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	-24000
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	-13000
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-6460000
CY2020	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-8795000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-181939000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-162585000
CY2019Q4	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	59638000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	5200000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	77212000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	120000
CY2020	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	12312000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	67158000
CY2020	atai	Foreign Currency Translation Adjustment Net Of Tax ForeignCurrencyTranslationAdjustmentNetOfTax	7232000
CY2020	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-178483000
CY2020Q4	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	95368000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	4900000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	140868000
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	7259000
CY2021	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	8411000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	935000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	63362000
CY2021	atai	Foreign Currency Translation Adjustment Net Of Tax ForeignCurrencyTranslationAdjustmentNetOfTax	-14179000
CY2021	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	-171690000
CY2021Q4	atai	Stockholder Equity Including Portion Attributable To Noncontrolling Interest StockholderEquityIncludingPortionAttributableToNoncontrollingInterest	385959000
CY2021	us-gaap	Profit Loss ProfitLoss	-174244000
CY2020	us-gaap	Profit Loss ProfitLoss	-178625000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	47000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	24000
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	195000
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	64000
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-173000
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1133000
CY2020	us-gaap	Increase Decrease In Notes Receivable Related Parties Current IncreaseDecreaseInNotesReceivableRelatedPartiesCurrent	718000
CY2020	atai	Change In Fair Value Of Convertible Promissory Note ChangeInFairValueOfConvertiblePromissoryNote	16974000
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-41000
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-150000
CY2021	atai	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-87000
CY2021	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-12346000
CY2020	us-gaap	Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount	19856000
CY2021	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	16923000
CY2021	atai	Loss On Conversion Of Convertible Notes LossOnConversionOfConvertibleNotes	513000
CY2021	us-gaap	Variable Interest Entity Initial Consolidation Gain Or Loss VariableInterestEntityInitialConsolidationGainOrLoss	3543000
CY2020	atai	Loss On Asset Acquisition Of A Variable Interest Entity LossOnAssetAcquisitionOfAVariableInterestEntity	-504000
CY2021	atai	Income Losses From Equity Method Investments IncomeLossesFromEquityMethodInvestments	58555000
CY2020	atai	Income Losses From Equity Method Investments IncomeLossesFromEquityMethodInvestments	76507000
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	15480000
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	12020000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	63362000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	67158000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	11346000
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	155000
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	43000
CY2020	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-96000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9699000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1150000
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	5973000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2300000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1704000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5756000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3896000
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	12000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-63246000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20766000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	173000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	59000
CY2021	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	955000
CY2021	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	47000
CY2020	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	276000
CY2021	us-gaap	Other Payments To Acquire Businesses OtherPaymentsToAcquireBusinesses	1000000
CY2021	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	52937000
CY2020	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	2088000
CY2021	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	11312000
CY2020	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	23920000
CY2021	us-gaap	Proceeds From Sale Of Land Held For Use ProceedsFromSaleOfLandHeldForUse	12346000
CY2020	us-gaap	Origination Of Notes Receivable From Related Parties OriginationOfNotesReceivableFromRelatedParties	226000
CY2020	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	1916000
CY2021	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	2600000
CY2021	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0
CY2020	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	338000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-81276000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-28271000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	409884000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	82439000
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	12350000
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1314000
CY2021	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0
CY2020	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0
CY2020	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	696000
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	534000
CY2021	atai	Proceeds From Sale Of Investment ProceedsFromSaleOfInvestment	2417000
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0
CY2020	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1022000
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0
CY2020	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	30437000
CY2020	atai	Proceeds From A Related Party Convertible Promissory Note ProceedsFromARelatedPartyConvertiblePromissoryNote	300000
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1588000
CY2020	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1044000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	935000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	120000
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	6854000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	409862000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	113052000
CY2021	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-320000
CY2020	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	3169000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	265020000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	67184000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97246000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30062000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	362266000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97246000
CY2021	atai	Common Stock Issuance Costs In Accounts Payable CommonStockIssuanceCostsInAccountsPayable	0
CY2020	atai	Common Stock Issuance Costs In Accounts Payable CommonStockIssuanceCostsInAccountsPayable	94000
CY2020	atai	Common Stock Issuance Costs In Accrued Liabilities CommonStockIssuanceCostsInAccruedLiabilities	3819000
CY2021	atai	Conversion Of Short Term Notes Receivable For Other Investments ConversionOfShortTermNotesReceivableForOtherInvestments	0
CY2020	atai	Conversion Of Short Term Notes Receivable For Other Investments ConversionOfShortTermNotesReceivableForOtherInvestments	9003000
CY2021	atai	Conversion Of Other Investments Into Equity Method Investments ConversionOfOtherInvestmentsIntoEquityMethodInvestments	0
CY2020	atai	Conversion Of Other Investments Into Equity Method Investments ConversionOfOtherInvestmentsIntoEquityMethodInvestments	53101000
CY2020	atai	Deferred Offering Costs In Accounts Payable DeferredOfferingCostsInAccountsPayable	358000
CY2021	atai	Deferred Offering Costs In Accrued Liabilities DeferredOfferingCostsInAccruedLiabilities	0
CY2020	atai	Deferred Offering Costs In Accrued Liabilities DeferredOfferingCostsInAccruedLiabilities	468000
CY2021	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	4761000
CY2020	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	12312000
CY2021	atai	Fair Value Of Non Controlling Interests Issued In Connection With Consolidation Of Variable Interest Entity FairValueOfNonControllingInterestsIssuedInConnectionWithConsolidationOfVariableInterestEntity	392000
CY2021	atai	Fair Value Of Redeemable Non Controlling Interests Issued In Connection With Consolidation Of Variable Interest Entity FairValueOfRedeemableNonControllingInterestsIssuedInConnectionWithConsolidationOfVariableInterestEntity	2555000
CY2021	atai	Issuance Of Common Shares In Connection With The Conversion Of Convertible Promissory Notes IssuanceOfCommonSharesInConnectionWithTheConversionOfConvertiblePromissoryNotes	0
CY2020	atai	Issuance Of Common Shares In Connection With The Conversion Of Convertible Promissory Notes IssuanceOfCommonSharesInConnectionWithTheConversionOfConvertiblePromissoryNotes	50059000
CY2021	atai	Issuance Of Subsidiary Shares In Connection With A Stock Purchase Agreement IssuanceOfSubsidiarySharesInConnectionWithAStockPurchaseAgreement	0
CY2020	atai	Issuance Of Subsidiary Shares In Connection With A Stock Purchase Agreement IssuanceOfSubsidiarySharesInConnectionWithAStockPurchaseAgreement	120000
CY2021Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	0
CY2021	atai	Issuance Of Subsidiary Shares In Connection With The Conversion Of Convertible Notes IssuanceOfSubsidiarySharesInConnectionWithTheConversionOfConvertibleNotes	3258000
CY2020	atai	Issuance Of Subsidiary Shares In Connection With The Conversion Of Convertible Notes IssuanceOfSubsidiarySharesInConnectionWithTheConversionOfConvertibleNotes	0
CY2021	atai	Exercise Of Hurdle Share Option Plan Award ExerciseOfHurdleShareOptionPlanAward	527000
CY2020	atai	Exercise Of Hurdle Share Option Plan Award ExerciseOfHurdleShareOptionPlanAward	0
CY2021	atai	Issuance Of Derivative Instrument Related To Convertible Promissory Notes IssuanceOfDerivativeInstrumentRelatedToConvertiblePromissoryNotes	646000
CY2020	atai	Issuance Of Derivative Instrument Related To Convertible Promissory Notes IssuanceOfDerivativeInstrumentRelatedToConvertiblePromissoryNotes	364000
CY2021	us-gaap	Nature Of Operations NatureOfOperations	<p id="notes" style="text-indent:0.0%;font-size:10.0pt;margin-top:4.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. Or</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ganization and Description of Business</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ATAI Life Sciences N.V. (“atai”) is the parent company of ATAI Life Sciences AG and, along with its subsidiaries, is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.75pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since inception, atai has either created wholly owned subsidiaries or has made investments in certain controlled entities, including variable interest entities (“VIEs”) for which atai is the primary beneficiary under the VIE model (collectively, the “Company”). atai is headquartered in Berlin, Germany.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has determined that it has one operating and reporting segment.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Corporate Reorganization and Initial Public Offering</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.4pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">atai was incorporated pursuant to the laws of the Netherlands as a Dutch private company with limited liability on September 10, 2020 for the purposes of becoming a holding company for ATAI Life Sciences AG and consummating the corporate reorganization described below. atai did not conduct any operations prior to the corporate reorganization other than activities incidental to its formation. ATAI Life Sciences AG was formed as a separate company on February 7, 2018.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.85pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In contemplation of the consummation of atai’s initial public offering (“IPO”) of common shares, atai undertook a corporate reorganization (the “Corporate Reorganization”). The Corporate Reorganization consisted of several steps as described below:</span></p><div style="margin-left:5.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.065%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.335229367461947%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exchange of ATAI Life Sciences AG Securities for ATAI Life Sciences B.V. Common Shares and Share Split</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: In April 2021, the existing shareholders of ATAI Life Sciences AG each became a party to a separate notarial deed of issue under Dutch law and (i) subscribed for new common shares in ATAI Life Sciences B.V. and (ii) transferred their respective shares in ATAI Life Sciences AG, on a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1 to 10 basis</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (the “Exchange Ratio”), to ATAI Life Sciences B.V. as a contribution in kind on the common shares in ATAI Life Sciences B.V. As a result of the issuance of common shares in ATAI Life Sciences B.V. to the shareholders of ATAI Life Sciences AG and the contribution and transfer of their respective shares in ATAI Life Sciences AG to ATAI Life Sciences B.V., ATAI Life Sciences AG became a wholly owned subsidiary of ATAI Life Sciences B.V. No shareholder rights or preferences changed as a result of the share for share exchange. In connection with such exchange, the common share in ATAI Life Sciences B.V. held by Apeiron was cancelled. On June 7, 2021, shares of ATAI Life Sciences B.V. were split applying a ratio of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6 to one</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and the nominal value of the shares was reduced to €</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, pursuant to a shareholders’ resolution and amendment to the articles of association.</span></div></div><div style="margin-left:5.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:5.065%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:5.335229367461947%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Conversion of ATAI Life Sciences B.V. into ATAI Life Sciences N.V</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.: Immediately preceding the Company’s IPO, the legal form of ATAI Life Sciences B.V. was converted from a Dutch private company with limited liability to a Dutch public company, and the articles of association of ATAI Life Sciences N.V., became effective. Following the Corporate Reorganization, ATAI Life Sciences N.V. became the holding company of ATAI Life Sciences AG.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.85pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1452083333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Corporate Reorganization, as described above, is considered a continuation of ATAI Life Sciences AG resulting in no change in the carrying values of assets or liabilities. As a result, the financial statements for periods prior to the Corporate Reorganization are the financial statements of ATAI Life Sciences AG as the predecessor to atai for accounting and reporting purposes. All share, per-share and related information presented in these consolidated financial statements and corresponding disclosure notes have been retrospectively adjusted, where applicable, to reflect the impact of the share exchange and share split resulting from the Corporate Reorganization. In connection with the Corporate Reorganization, outstanding share awards and option grants of ATAI Life Sciences AG were exchanged for share awards and option grants of ATAI Life Sciences B.V. with identical restrictions.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:1.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1452083333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On June 22, 2021, atai closed the IPO of its common stock on the Nasdaq Stock Market ("Nasdaq"). As part of the IPO, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock, which included </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares sold pursuant to the exercise of the underwriters’ over-allotment option, at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The Company received net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">231.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million from the IPO, after deducting underwriters’ discounts and commissions of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and offering costs of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.15pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impact of COVID-19 Pandemic</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1452083333333332;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic has continued to present global public health and economic challenges during the twelve months ended December 31, 2021. Although some research and development timelines have been impacted by delays related to the COVID-19 pandemic, the Company has not experienced material financial impacts on its business and operations as a result. The Company continues to monitor the impact of the COVID-19 pandemic on its employees and business and has undertaken business continuity measures to mitigate potential disruption to its operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The future impact of COVID-19 on the Company’s business and operations, including its research and development programs and related clinical trials, will largely depend on future developments, which are highly uncertain, such as the duration of the pandemic, the spread of the disease and variants thereof, the availability and effectiveness of vaccines and related roll-out efforts, breakthrough infections among the vaccinated, vaccine hesitancy, the implementation of vaccine mandates, travel restrictions, social distancing and related government actions around the world, business closures or business disruptions and the ultimate impact of COVID-19 on financial markets and the global economy. For a discussion of the risks to the Company's business from COVID-19, refer to the section titled “Risk Factors” in Part I, Item 1A.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidity and Going Concern</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has incurred significant losses and negative cash flows from operations since its inception. As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">362.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and its accumulated deficit was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">357.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company has historically financed its operations through the sale of equity securities, sale of convertible notes and revenue generated from licensing and collaboration arrangements. The Company has not generated any revenues to date from the sale of its product candidates and does not anticipate generating any revenues from the sale of its product candidates unless and until it successfully completes development and obtains regulatory approval to market its product candidates.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.75pt;line-height:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company currently expects that its existing cash and cash equivalents as of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date the consolidated financial statements are issued.</span></p>
CY2021	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	1 to 10 basis
CY2021Q2	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	1.6 to one
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.10
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	362300000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-357800000
CY2021Q4	atai	Noncontrolling Interest Ownership Percentage NoncontrollingInterestOwnershipPercentage	1
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:11.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;line-height:5.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to the fair value of the Company’s short term notes receivable—related party with COMPASS Pathways plc, investment in Intelgenx Technologies Corp. (“IntelGenx”), warrant liability with Neuronasal Inc., convertible promissory notes issued in connection with the 2020 convertible note agreement (the “2020 Convertible Notes”), contingent consideration liability—related parties, derivative liability associated with the Perception convertible promissory notes, in-process research and development assets (“IPRD”), redeemable noncontrolling interests and noncontrolling interests recognized in acquisitions, the valuations of common shares prior to IPO and share-based awards, and accruals for research and development costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.<br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, the Company assessed the impact that the COVID-19 pandemic has had on its operations and financial results as of December 31, 2021 and through the issuance of these consolidated financial statements. The Company’s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and expenses. The Company has not experienced any significant financial impacts due to COVID-19.</span></p>
CY2021	atai	Risks And Uncertainties RisksAndUncertainties	<p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risks and Uncertainties</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company is subject to risks common to companies in the biopharmaceutical industry. The Company believes that changes in any of the following areas could have a material adverse effect on future financial position or results of operations: ability to obtain future financing;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approval and market acceptance of, and reimbursement for, product candidates; performance of third-party clinical research organizations and manufacturers upon which the Company relies; protection of the Company’s intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; and the Company’s ability to attract and retain employees.</span></p>
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments which potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and all notes receivables. The Company’s cash is mainly held in financial institutions in the United States, United Kingdom, Germany and Australia. Amounts on deposit may at times exceed federally insured limits. The credit risk associated with the Company’s investment in all notes receivables is deemed to be limited based on the Company’s evaluation and monitoring of the liquidity and capital resources of the counterparties. The Company has not experienced any credit losses related to these financial instruments and does not believe that it is exposed to any significant credit risk related to these instruments.</span></p>
CY2021	atai	Impairment Loss Recognized ImpairmentLossRecognized	0
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	0
CY2020Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	800000
CY2020Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	4600000
CY2021Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	8000
CY2021Q1	us-gaap	Notes Receivable Related Parties Noncurrent NotesReceivableRelatedPartiesNoncurrent	100000
CY2021	atai	Purchasesofcommonstock Purchasesofcommonstock	500000
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	500000
CY2021Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.80
CY2020Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.80
CY2019Q4	us-gaap	Minority Interest MinorityInterest	887000
CY2020	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	12312000
CY2020	atai	Net Income Loss Attributable To Noncontrolling Interest Common NetIncomeLossAttributableToNoncontrollingInterestCommon	-6508000
CY2020	atai	Net Income Loss Attributable To Noncontrolling Interest Preferred NetIncomeLossAttributableToNoncontrollingInterestPreferred	-2132000
CY2020	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	-13000
CY2020Q4	us-gaap	Minority Interest MinorityInterest	4546000
CY2021	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	8411000
CY2021	atai	Net Income Loss Attributable To Noncontrolling Interest Common NetIncomeLossAttributableToNoncontrollingInterestCommon	-5153000
CY2021	atai	Net Income Loss Attributable To Noncontrolling Interest Preferred NetIncomeLossAttributableToNoncontrollingInterestPreferred	1271000
CY2021	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	-24000
CY2021Q4	us-gaap	Minority Interest MinorityInterest	9051000
CY2021Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	0
CY2020Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	0
CY2019Q4	us-gaap	Redeemable Noncontrolling Interest Equity Redemption Value RedeemableNoncontrollingInterestEquityRedemptionValue	142000
CY2020	atai	Net Loss Attributable To Redeemable Noncontrolling Interestspreferred NetLossAttributableToRedeemableNoncontrollingInterestspreferred	-142000
CY2020Q4	us-gaap	Redeemable Noncontrolling Interest Equity Redemption Value RedeemableNoncontrollingInterestEquityRedemptionValue	0
CY2021	atai	Issuance Of Redeemable Noncontrolling Interests IssuanceOfRedeemableNoncontrollingInterests	2555000
CY2021	atai	Net Loss Attributable To Redeemable Noncontrolling Interests Common NetLossAttributableToRedeemableNoncontrollingInterestsCommon	-2555000
CY2021Q4	us-gaap	Redeemable Noncontrolling Interest Equity Redemption Value RedeemableNoncontrollingInterestEquityRedemptionValue	0
CY2021Q4	us-gaap	Variable Interest Entity Entity Maximum Loss Exposure Amount VariableInterestEntityEntityMaximumLossExposureAmount	11600000
CY2021Q4	us-gaap	Variable Interest Difference Between Carrying Amount And Maximum Exposure VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure	3800000
CY2020Q4	us-gaap	Variable Interest Entity Entity Maximum Loss Exposure Amount VariableInterestEntityEntityMaximumLossExposureAmount	8000000.0
CY2020Q4	us-gaap	Variable Interest Difference Between Carrying Amount And Maximum Exposure VariableInterestDifferenceBetweenCarryingAmountAndMaximumExposure	200000
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	16131000
CY2021Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	11628000
CY2020Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	8044000
CY2021	atai	Equity Method Investment Shares Transaction Date EquityMethodInvestmentSharesTransactionDate	2026-12-31
CY2021	us-gaap	Subsidiary Or Equity Method Investee Cumulative Proceeds Received On All Transactions SubsidiaryOrEquityMethodInvesteeCumulativeProceedsReceivedOnAllTransactions	9600000
CY2021	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	2400000
CY2020Q4	us-gaap	Shares Outstanding SharesOutstanding	7052003
CY2020Q4	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	378100000
CY2021Q2	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3000000.0
CY2021Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	9000000.0
	atai	Change In Fair Value Of Short Term Notes Receivable ChangeInFairValueOfShortTermNotesReceivable	700000
CY2021Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	100000
CY2021Q2	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Net EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet	800000
CY2020Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Net EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet	200000
CY2021Q2	atai	Fair Value Of Common Stock By Applying Discount For Lack Of Marketability FairValueOfCommonStockByApplyingDiscountForLackOfMarketability	0.137
CY2021Q4	atai	Fair Value Of Common Stock By Applying Discount For Lack Of Marketability FairValueOfCommonStockByApplyingDiscountForLackOfMarketability	0.050
CY2021Q4	atai	Prepaid Research And Development Related Expenses PrepaidResearchAndDevelopmentRelatedExpenses	2692000
CY2020Q4	atai	Prepaid Research And Development Related Expenses PrepaidResearchAndDevelopmentRelatedExpenses	313000
CY2021Q4	atai	Research And Development Tax Credit Current ResearchAndDevelopmentTaxCreditCurrent	742000
CY2020Q4	atai	Research And Development Tax Credit Current ResearchAndDevelopmentTaxCreditCurrent	556000
CY2021Q4	us-gaap	Prepaid Taxes PrepaidTaxes	4664000
CY2020Q4	us-gaap	Prepaid Taxes PrepaidTaxes	509000
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	3049000
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	144000
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	756000
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	554000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11903000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2076000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2667000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2858000
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	8137000
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	997000
CY2021Q4	atai	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	861000
CY2020Q4	atai	Accrued External Research And Development Expenses Current AccruedExternalResearchAndDevelopmentExpensesCurrent	347000
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2832000
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1098000
CY2021Q4	atai	Accrued Advisory Fees Current AccruedAdvisoryFeesCurrent	169000
CY2020Q4	atai	Accrued Advisory Fees Current AccruedAdvisoryFeesCurrent	3819000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	163000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	96000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14829000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9215000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-5000
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-18000
CY2021Q4	us-gaap	Convertible Debt ConvertibleDebt	743000
CY2020Q4	us-gaap	Convertible Debt ConvertibleDebt	1199000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.740
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	atai	Conversion Payments ConversionPayments	17
CY2021Q4	us-gaap	Share Price SharePrice	75
CY2020Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	4.69
CY2020Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	5.56
CY2020Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	77200000
CY2020Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	32200000
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	152200000
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4900000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	34026163
	atai	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Exchanged ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesExchanged	1152192
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	400000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-89061000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-75966000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-47540000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-25847000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-136601000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-101813000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2021	atai	Expenses Not Deductible For Tax Purposes ExpensesNotDeductibleForTaxPurposes	612000
CY2020	atai	Income Tax Reconciliation Expected Income Tax Expense Benefit IncomeTaxReconciliationExpectedIncomeTaxExpenseBenefit	-30722000
CY2021	atai	Income Tax Reconciliation State Income Taxes Net Of Federal Tax Benefit And Valuation Allowance IncomeTaxReconciliationStateIncomeTaxesNetOfFederalTaxBenefitAndValuationAllowance	132000
CY2020	atai	Income Tax Reconciliation State Income Taxes Net Of Federal Tax Benefit And Valuation Allowance IncomeTaxReconciliationStateIncomeTaxesNetOfFederalTaxBenefitAndValuationAllowance	74000
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	4222000
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	2304000
CY2021	atai	Effect Of Taxes Not Provided On Outside Basis Differences In Consolidated Subsidiaries Regarding Fair Value Adjustments EffectOfTaxesNotProvidedOnOutsideBasisDifferencesInConsolidatedSubsidiariesRegardingFairValueAdjustments	0
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1117000
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	305000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	1117000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	305000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-5106000
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5106000
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3989000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	305000
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-136601000
CY2020	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-101813000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3018
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3018
CY2021	atai	Income Tax Reconciliation Expected Income Tax Expense Benefit IncomeTaxReconciliationExpectedIncomeTaxExpenseBenefit	-41220000
CY2020	atai	Effect Of Taxes Not Provided On Outside Basis Differences In Consolidated Subsidiaries Regarding Fair Value Adjustments EffectOfTaxesNotProvidedOnOutsideBasisDifferencesInConsolidatedSubsidiariesRegardingFairValueAdjustments	-247000
CY2021	atai	Effect Of Taxes Not Provided On Outside Basis Differences In Consolidated Subsidiaries Regarding Ipr D Charges And Acquisition Adjustments EffectOfTaxesNotProvidedOnOutsideBasisDifferencesInConsolidatedSubsidiariesRegardingIprDChargesAndAcquisitionAdjustments	3251000
CY2020	atai	Effect Of Taxes Not Provided On Outside Basis Differences In Consolidated Subsidiaries Regarding Ipr D Charges And Acquisition Adjustments EffectOfTaxesNotProvidedOnOutsideBasisDifferencesInConsolidatedSubsidiariesRegardingIprDChargesAndAcquisitionAdjustments	2164000
CY2021	atai	Effect Of Australian Rd Tax Credit Incentives EffectOfAustralianRDTaxCreditIncentives	-3000
CY2020	atai	Effect Of Australian Rd Tax Credit Incentives EffectOfAustralianRDTaxCreditIncentives	240000
CY2021	atai	Effect Of Taxes Not Provided On Outside Basis Differences In Investments Regarding Fair Value Adjustments EffectOfTaxesNotProvidedOnOutsideBasisDifferencesInInvestmentsRegardingFairValueAdjustments	2934000
CY2020	atai	Effect Of Taxes Not Provided On Outside Basis Differences In Investments Regarding Fair Value Adjustments EffectOfTaxesNotProvidedOnOutsideBasisDifferencesInInvestmentsRegardingFairValueAdjustments	-6175000
CY2021	atai	Effect Of Statutory Accounting Adjustments EffectOfStatutoryAccountingAdjustments	-10409000
CY2021	atai	Compensation Expenses Not Deductible Under Irc Sections CompensationExpensesNotDeductibleUnderIrcSections	1690000
CY2020	atai	Expenses Not Deductible For Tax Purposes ExpensesNotDeductibleForTaxPurposes	-55000
CY2020	atai	Effect Of German Participation Exemption On Outside Basis Differences EffectOfGermanParticipationExemptionOnOutsideBasisDifferences	-5000
CY2020	atai	Effect Of Non Deductible Compensation In Respect Of Convertible Notes EffectOfNonDeductibleCompensationInRespectOfConvertibleNotes	18558000
CY2020	atai	Effect Of Conversion Of Convertible Notes EffectOfConversionOfConvertibleNotes	4846000
CY2021	atai	Effect Of Share Based Compensation Expense EffectOfShareBasedCompensationExpense	192000
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Other IncomeTaxReconciliationTaxCreditsOther	657000
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Other IncomeTaxReconciliationTaxCreditsOther	1000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	35267000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	9324000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3989000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	305000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	8451000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	52000
CY2021Q4	atai	Deferred Tax Liabilities Other Taxable Timing Difference DeferredTaxLiabilitiesOtherTaxableTimingDifference	-17000
CY2020Q4	atai	Deferred Tax Liabilities Other Taxable Timing Difference DeferredTaxLiabilitiesOtherTaxableTimingDifference	-51000
CY2021Q4	atai	Deferred Tax Liabilities Unrealised Foreign Exchange DeferredTaxLiabilitiesUnrealisedForeignExchange	-3326000
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0292
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0030
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	66000
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	57000
CY2021Q4	atai	Deferred Tax Assets Stock Based Compensation DeferredTaxAssetsStockBasedCompensation	17231000
CY2020Q4	atai	Deferred Tax Assets Stock Based Compensation DeferredTaxAssetsStockBasedCompensation	1698000
CY2021Q4	atai	Deferred Tax Assets Other Deductible Timing Differences DeferredTaxAssetsOtherDeductibleTimingDifferences	829000
CY2020Q4	atai	Deferred Tax Assets Other Deductible Timing Differences DeferredTaxAssetsOtherDeductibleTimingDifferences	194000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	57893000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	14226000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	49442000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14174000
CY2020Q4	atai	Deferred Tax Liabilities Unrealised Foreign Exchange DeferredTaxLiabilitiesUnrealisedForeignExchange	0
CY2021Q4	atai	Deferred Tax Liabilities Outside Basis Differences In Equity And Other Investments DeferredTaxLiabilitiesOutsideBasisDifferencesInEquityAndOtherInvestments	-2000
CY2020Q4	atai	Deferred Tax Liabilities Outside Basis Differences In Equity And Other Investments DeferredTaxLiabilitiesOutsideBasisDifferencesInEquityAndOtherInvestments	-1000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3345000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	52000
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	5106000
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14200000
CY2021Q4	atai	Unremitted Earnings UnremittedEarnings	0
CY2020Q4	atai	Unremitted Earnings UnremittedEarnings	0
CY2021	atai	Federal Tax Loss Carryforward FederalTaxLossCarryforward	103232000
CY2020	atai	Federal Tax Loss Carryforward FederalTaxLossCarryforward	19738000
CY2021	atai	Overseas Tax Loss Carryforward OverseasTaxLossCarryforward	31875000
CY2020	atai	Overseas Tax Loss Carryforward OverseasTaxLossCarryforward	21425000
CY2021	atai	Tax Loss Carryforward TaxLossCarryforward	135107000
CY2020	atai	Tax Loss Carryforward TaxLossCarryforward	41163000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021	us-gaap	Profit Loss ProfitLoss	-174244000
CY2020	us-gaap	Profit Loss ProfitLoss	-178625000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-6436000
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-8782000
CY2021	atai	Net Income Attributable To Common Stockholders Basic And Diluted NetIncomeAttributableToCommonStockholdersBasicAndDiluted	-167808000
CY2020	atai	Net Income Attributable To Common Stockholders Basic And Diluted NetIncomeAttributableToCommonStockholdersBasicAndDiluted	-169843000
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	138265859
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	93019072
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.21
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.83
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	44388892
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27331232
CY2020Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	4.69
CY2020Q3	atai	Related Party Reservation Rate Of Common Shares For Ipo RelatedPartyReservationRateOfCommonSharesForIpo	0.27

Files In Submission

Name	View Source	Status
0000950170-22-005013-index-headers.html	Edgar Link	pending
0000950170-22-005013-index.html	Edgar Link	pending
0000950170-22-005013.txt	Edgar Link	pending
0000950170-22-005013-xbrl.zip	Edgar Link	pending
atai-20211231.htm	Edgar Link	pending
atai-20211231.xsd	Edgar Link	pending
atai-20211231_cal.xml	Edgar Link	unprocessable
atai-20211231_def.xml	Edgar Link	unprocessable
atai-20211231_htm.xml	Edgar Link	completed
atai-20211231_lab.xml	Edgar Link	unprocessable
atai-20211231_pre.xml	Edgar Link	unprocessable
atai-ex21_1.htm	Edgar Link	pending
atai-ex23_1.htm	Edgar Link	pending
atai-ex23_2.htm	Edgar Link	pending
atai-ex31_1.htm	Edgar Link	pending
atai-ex31_2.htm	Edgar Link	pending
atai-ex32_1.htm	Edgar Link	pending
atai-ex32_2.htm	Edgar Link	pending
atai-ex4_2.htm	Edgar Link	pending
atai-ex99_1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
img104120494_0.jpg	Edgar Link	pending
img104120494_1.jpg	Edgar Link	pending
img104120494_2.jpg	Edgar Link	pending
img104120494_3.jpg	Edgar Link	pending
img104120494_4.jpg	Edgar Link	pending
img104120494_5.jpg	Edgar Link	pending
img104120494_6.jpg	Edgar Link	pending
img104120494_7.jpg	Edgar Link	pending
img104120494_8.jpg	Edgar Link	pending
img104120494_9.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATAI
ATAI Life Sciences NV Stock $atai

2022 Q1 Form 10-K Financial Statement

#000095017022005013 Filed on March 30, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATAI ATAI Life Sciences NV Stock $atai

2022 Q1 Form 10-K Financial Statement

#000095017022005013 Filed on March 30, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATAI
ATAI Life Sciences NV Stock $atai